• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

类风湿关节炎影像学进展的稳健分析。

Robust analyses for radiographic progression in rheumatoid arthritis.

机构信息

Clinical Immunology & Rheumatology, University of Amsterdam, Amsterdam, Netherlands

Rheumatology, Atrium Medical Centre, Heerlen, Netherlands.

出版信息

RMD Open. 2023 Apr;9(2). doi: 10.1136/rmdopen-2022-002543.

DOI:10.1136/rmdopen-2022-002543
PMID:37015757
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10083852/
Abstract

Demonstrating inhibition of the structural damage to joints as a statistically significant difference in radiographic progression as measured by the van der Heijde modified Total Sharp Score (mTSS) is a common objective in trials for rheumatoid arthritis treatments. The frequently used analysis of the covariance model with missing data imputed using linear extrapolation (analyses of covariance, ANCOVA+LE) may not be ideal for long-term extension studies or for paediatric studies. The random coefficient (RC) model may represent a better alternative.A two-arm (active treatment and placebo) setting with a week 44 study period was considered. RC model, ANCOVA+LE and ANCOVA with last observation carried forward imputation were compared under different scenarios in bias, root mean square error (RMSE), power and type I error rate.The RC model outperformed ANCOVA+LE in metrics measuring bias, RMSE, power and type I error rate under the evaluated scenarios. ANCOVA and RC provide similar performance when there are no missing data. With missing data, RC+observed (OBS) provides similar or better results than ANCOVA+LE in power and bias.Our simulations support that RC is both a more sensitive and a more precise alternative to the commonly used ANCOVA+LE as a primary method for analysing mTSS in long-term extension and paediatric studies with a higher likelihood of missing data. The RC model can provide a reference at time points with missing data by estimating a slope; mTSS change by one unit change in time. ANCOVA+LE is recommended as a sensitivity analysis.

摘要

在类风湿关节炎治疗的试验中,通常的目标是证明对关节结构损伤的抑制作用,这种抑制作用在放射学进展方面表现为 van der Heijde 改良总 Sharp 评分(mTSS)的统计学显著差异。在长期扩展研究或儿科研究中,经常使用缺失数据采用线性外推法(协方差分析,ANCOVA+LE)进行插补的协方差分析模型(analysis of covariance,ANCOVA+LE)可能不是理想的选择。随机系数(random coefficient,RC)模型可能是更好的选择。

考虑了一个为期 44 周的研究期的两臂(活性治疗和安慰剂)设置。在不同的偏差、均方根误差(root mean square error,RMSE)、功效和Ⅰ型错误率的场景下,对 RC 模型、ANCOVA+LE 和采用末次观测值结转(last observation carried forward imputation,LOCF)的 ANCOVA 进行了比较。

在评估的场景下,RC 模型在衡量偏差、RMSE、功效和Ⅰ型错误率的指标方面优于 ANCOVA+LE。当没有缺失数据时,ANCOVA 和 RC 提供相似的性能。在存在缺失数据的情况下,RC+观测(OBS)在功效和偏差方面提供了与 ANCOVA+LE 相似或更好的结果。

我们的模拟支持 RC 是一种更敏感、更精确的替代方法,比常用的 ANCOVA+LE 更适合对存在更高缺失数据可能性的长期扩展和儿科研究中的 mTSS 进行主要分析。RC 模型可以通过估计斜率来提供缺失数据点的参考;时间上 mTSS 随一个单位的变化而变化。建议使用 ANCOVA+LE 作为敏感性分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e62/10083852/469e0ba1572e/rmdopen-2022-002543f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e62/10083852/4c2bf81c84ca/rmdopen-2022-002543f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e62/10083852/c0f6d1fabfdf/rmdopen-2022-002543f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e62/10083852/27646d74bbab/rmdopen-2022-002543f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e62/10083852/469e0ba1572e/rmdopen-2022-002543f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e62/10083852/4c2bf81c84ca/rmdopen-2022-002543f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e62/10083852/c0f6d1fabfdf/rmdopen-2022-002543f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e62/10083852/27646d74bbab/rmdopen-2022-002543f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e62/10083852/469e0ba1572e/rmdopen-2022-002543f04.jpg

相似文献

1
Robust analyses for radiographic progression in rheumatoid arthritis.类风湿关节炎影像学进展的稳健分析。
RMD Open. 2023 Apr;9(2). doi: 10.1136/rmdopen-2022-002543.
2
Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis.在临床试验中,对类风湿关节炎患者缺失的影像学变化评分进行线性外推,并不会虚假高估组间影像学变化。
Rheumatology (Oxford). 2016 Jul;55(7):1295-300. doi: 10.1093/rheumatology/kew030. Epub 2016 Apr 4.
3
Missing radiographic data handling in randomized clinical trials in rheumatoid arthritis.类风湿关节炎随机临床试验中缺失影像学数据的处理
J Biopharm Stat. 2013;23(6):1435-52. doi: 10.1080/10543406.2013.834913.
4
Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials.在现代类风湿性关节炎试验中,影像学进展仍是一个可靠的结果指标吗?托法替布临床试验的经验。
Arthritis Res Ther. 2016 Sep 23;18(1):212. doi: 10.1186/s13075-016-1106-y.
5
The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist, and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score.类风湿关节炎手指、手腕和脚趾关节结构损伤的磁共振成像及放射学评分的最小可检测差异和对变化的敏感性:应用于不同关节组合的OMERACT类风湿关节炎磁共振成像评分与Sharp/van der Heijde放射学评分的比较
Arthritis Rheum. 2005 Aug;52(8):2300-6. doi: 10.1002/art.21207.
6
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.不同插补方法对银屑病关节炎患者影像学进展评估的影响:培塞利珠单抗治疗银屑病关节炎 24 周、III 期、双盲、安慰剂对照研究的结果。
Ann Rheum Dis. 2014 Jan;73(1):233-7. doi: 10.1136/annrheumdis-2013-203697. Epub 2013 Aug 13.
7
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.巴利替尼与安慰剂或阿达木单抗治疗类风湿关节炎的疗效比较。
N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.
8
Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.临床试验中影像学结果数据的呈现与分析:来自TEMPO研究的经验
Arthritis Rheum. 2005 Jan;52(1):49-60. doi: 10.1002/art.20775.
9
Issues involved in a metaanalysis of rheumatoid arthritis radiographic progression. Analysis issues.类风湿关节炎影像学进展的荟萃分析中涉及的问题。分析问题。
J Rheumatol. 2000 Feb;27(2):544-8; discussion 552.
10
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.在类风湿关节炎中用乌帕替尼抑制结构性关节损伤进展:SELECT 3 期项目的 1 年结果。
Rheumatology (Oxford). 2022 Aug 3;61(8):3246-3256. doi: 10.1093/rheumatology/keab861.

本文引用的文献

1
Adjustment for baseline value in longitudinal randomised trials.纵向随机试验中基线值的调整
Tidsskr Nor Laegeforen. 2022 Apr 4;142(6). doi: 10.4045/tidsskr.21.0824. Print 2022 Apr 5.
2
Prevention and cure: The major unmet needs in the management of rheumatoid arthritis.防治:类风湿关节炎管理中未满足的主要需求。
J Autoimmun. 2020 Jun;110:102399. doi: 10.1016/j.jaut.2019.102399. Epub 2019 Dec 31.
3
Last observation carried forward.末次观察值结转
Tidsskr Nor Laegeforen. 2019 May 23;139(9). doi: 10.4045/tidsskr.19.0061. Print 2019 May 28.
4
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.巴瑞替尼对类风湿关节炎患者且对传统合成抗风湿药物反应不足时1年结构关节损伤影像学进展的影响。
RMD Open. 2018 May 8;4(1):e000662. doi: 10.1136/rmdopen-2018-000662. eCollection 2018.
5
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.巴利替尼与安慰剂或阿达木单抗治疗类风湿关节炎的疗效比较。
N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.
6
To condition or not condition? Analysing 'change' in longitudinal randomised controlled trials.是否进行条件设定?分析纵向随机对照试验中的“变化”
BMJ Open. 2016 Dec 30;6(12):e013096. doi: 10.1136/bmjopen-2016-013096.
7
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.巴利昔替尼、甲氨蝶呤或联合治疗类风湿关节炎患者,且这些患者既往无或有限的疾病修饰抗风湿药物治疗史。
Arthritis Rheumatol. 2017 Mar;69(3):506-517. doi: 10.1002/art.39953.
8
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.EULAR 推荐的治疗类风湿关节炎的合成和生物疾病修饰抗风湿药物:2013 更新版。
Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.
9
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.2008年美国风湿病学会关于使用改善病情抗风湿药和生物制剂治疗类风湿关节炎的建议的2012年更新版。
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641.
10
Current understanding of rheumatoid arthritis therapy.类风湿关节炎治疗的现有认识。
Clin Pharmacol Ther. 2012 Apr;91(4):607-20. doi: 10.1038/clpt.2011.325. Epub 2012 Feb 22.